Tectonic Therapeutic, Inc.
Regulated industrySells to businessesDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $20.08
- 52-Week Range
- $16.77 – $39.53
- Market Cap
- $411.32M
- P/E (TTM)
- —
- EPS (TTM)
- -4.63
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 1.83
- PEG Ratio
- —
- Return on Equity
- -35.46%
- Return on Assets
- -23.16%
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Profit Margin
- 0.00%
- Current Ratio
- 19.71
- Debt/Equity
- 0.02
- Total Debt
- $3.92M
- Free Cash Flow
- $-45.45M
- Revenue Growth
- —
- Earnings Growth
- —
- Enterprise Value
- $188.96M
Market Snapshot
About
Tectonic Therapeutic, Inc. is a biotechnology company focused on developing novel therapeutics targeting G protein-coupled receptors (GPCRs). The company uses its proprietary GEODe platform to discover and develop medicines for diseases with significant unmet medical needs. Tectonic is advancing a pipeline of drug candidates in oncology, inflammation, and metabolic diseases.